+91-22-48913909Best Pharma Mutual Funds in India 2026
The pharma sector is often called India’s “sunrise industry” – it not only meets domestic healthcare needs but also supplies medicines to the world. For investors, this sector has delivered resilience during crises (like Covid-19) and continues to show strong long-term growth potential.
That’s where Pharma Mutual Funds come in. These are sectoral funds that invest in pharmaceutical, healthcare, and allied companies, giving you exposure to one of India’s most promising industries.
But are they right for your Portfolio? Let’s explore.
What are Pharma Mutual Funds?
Pharma Mutual Funds are sectoral Equity Funds that invest primarily in companies from:
- Pharmaceuticals
- Biotechnology
- Hospitals & healthcare services
- Medical equipment & diagnostics
Since they are sector-specific, they carry higher risk than Diversified Funds, but also offer the chance to capture outsized gains when the sector outperforms.
Why Invest in Pharma Sector Funds?
Here’s why the Indian pharma industry is considered a strong bet:
1. India: The Pharmacy of the World
- India supplies 20% of global generic medicines and is the largest vaccine manufacturer.
- Nearly 40% of US generic drug demand is met by Indian companies.
2. Rising Domestic Demand
- With growing middle-class income, lifestyle changes, and rising health awareness, healthcare spending in India is expected to rise sharply.
- health insurance penetration is improving, further fuelling demand.
3. Government Push
- Schemes like PLI (Production Linked Incentives) aim to boost domestic manufacturing of critical drugs and APIs.
- Ayushman Bharat and other healthcare programmes are expanding access.
4. Export Growth & Innovation
- Indian pharma is moving up the value chain with biosimilars, specialty drugs, and contract research.
- Exports remain a major driver – particularly to regulated markets like the US and EU.
In short: Pharma funds allow you to benefit from both domestic consumption growth and global demand for cost-effective drugs.
Talk to our investment specialist
Fund Selection Methodology used to find 10 funds
Best Pharma Sector Funds 2026
Fund NAV Net Assets (Cr) 3 MO (%) 6 MO (%) 1 YR (%) 3 YR (%) 5 YR (%) 2025 (%) TATA India Pharma & Healthcare Fund Growth ₹33.4268
↓ -0.16 ₹1,541 7.8 12.8 8.5 19 12.9 -4.9 Nippon India Pharma Fund Growth ₹570.737
↓ -3.30 ₹9,279 7.5 12.8 10.7 18.3 12.5 -3.3 SBI Healthcare Opportunities Fund Growth ₹519.215
↓ -3.84 ₹5,400 12.6 22.4 20.1 23.4 17.1 -3.5 UTI Healthcare Fund Growth ₹342.841
↓ -1.33 ₹1,371 12.1 23.2 17.2 23.9 15 -3.1 Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 4 Sep 26 Research Highlights & Commentary of 4 Funds showcased
Commentary TATA India Pharma & Healthcare Fund Nippon India Pharma Fund SBI Healthcare Opportunities Fund UTI Healthcare Fund Point 1 Lower mid AUM (₹1,541 Cr). Highest AUM (₹9,279 Cr). Upper mid AUM (₹5,400 Cr). Bottom quartile AUM (₹1,371 Cr). Point 2 Established history (10+ yrs). Established history (22+ yrs). Established history (21+ yrs). Oldest track record among peers (27 yrs). Point 3 Not Rated. Top rated. Rating: 2★ (upper mid). Rating: 1★ (lower mid). Point 4 Risk profile: High. Risk profile: High. Risk profile: High. Risk profile: High. Point 5 5Y return: 12.94% (lower mid). 5Y return: 12.53% (bottom quartile). 5Y return: 17.10% (top quartile). 5Y return: 15.01% (upper mid). Point 6 3Y return: 18.96% (lower mid). 3Y return: 18.31% (bottom quartile). 3Y return: 23.44% (upper mid). 3Y return: 23.91% (top quartile). Point 7 1Y return: 8.54% (bottom quartile). 1Y return: 10.69% (lower mid). 1Y return: 20.05% (top quartile). 1Y return: 17.20% (upper mid). Point 8 Alpha: -8.33 (bottom quartile). Alpha: -4.06 (lower mid). Alpha: 3.75 (top quartile). Alpha: 0.66 (upper mid). Point 9 Sharpe: 0.22 (lower mid). Sharpe: 0.18 (bottom quartile). Sharpe: 0.71 (top quartile). Sharpe: 0.51 (upper mid). Point 10 Information ratio: -0.58 (lower mid). Information ratio: -1.14 (bottom quartile). Information ratio: 0.02 (upper mid). Information ratio: 0.05 (top quartile). TATA India Pharma & Healthcare Fund
Nippon India Pharma Fund
SBI Healthcare Opportunities Fund
UTI Healthcare Fund
All the funds mentioned above are ideal, we are giving you detailed analysis of 3 funds.
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. Research Highlights for TATA India Pharma & Healthcare Fund Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Research Highlights for Nippon India Pharma Fund Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on (Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. Research Highlights for SBI Healthcare Opportunities Fund Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on (Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. Research Highlights for UTI Healthcare Fund Below is the key information for UTI Healthcare Fund Returns up to 1 year are on 1. TATA India Pharma & Healthcare Fund
TATA India Pharma & Healthcare Fund
Growth Launch Date 28 Dec 15 NAV (04 Sep 26) ₹33.4268 ↓ -0.16 (-0.49 %) Net Assets (Cr) ₹1,541 on 31 Jul 26 Category Equity - Sectoral AMC Tata Asset Management Limited Rating Risk High Expense Ratio 2.13 Sharpe Ratio 0.22 Information Ratio -0.58 Alpha Ratio -8.33 Min Investment 5,000 Min SIP Investment 150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) Growth of 10,000 investment over the years.
Date Value Returns for TATA India Pharma & Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Sep 26 Duration Returns 1 Month -1.4% 3 Month 7.8% 6 Month 12.8% 1 Year 8.5% 3 Year 19% 5 Year 12.9% 10 Year 15 Year Since launch 12% Historical performance (Yearly) on absolute basis
Year Returns 2025 -4.9% 2024 40.4% 2023 36.6% 2022 -8% 2021 19.1% 2020 64.4% 2019 5.5% 2018 -2.6% 2017 4.7% 2016 -14.7% Fund Manager information for TATA India Pharma & Healthcare Fund
Name Since Tenure Data below for TATA India Pharma & Healthcare Fund as on 31 Jul 26
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 2. Nippon India Pharma Fund
Nippon India Pharma Fund
Growth Launch Date 5 Jun 04 NAV (04 Sep 26) ₹570.737 ↓ -3.30 (-0.57 %) Net Assets (Cr) ₹9,279 on 31 Jul 26 Category Equity - Sectoral AMC Nippon Life Asset Management Ltd. Rating ☆☆ Risk High Expense Ratio 1.81 Sharpe Ratio 0.18 Information Ratio -1.14 Alpha Ratio -4.06 Min Investment 5,000 Min SIP Investment 100 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value Returns for Nippon India Pharma Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Sep 26 Duration Returns 1 Month -0.2% 3 Month 7.5% 6 Month 12.8% 1 Year 10.7% 3 Year 18.3% 5 Year 12.5% 10 Year 15 Year Since launch 19.9% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.3% 2024 34% 2023 39.2% 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% Fund Manager information for Nippon India Pharma Fund
Name Since Tenure Data below for Nippon India Pharma Fund as on 31 Jul 26
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 3. SBI Healthcare Opportunities Fund
SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (04 Sep 26) ₹519.215 ↓ -3.84 (-0.73 %) Net Assets (Cr) ₹5,400 on 31 Jul 26 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 1.97 Sharpe Ratio 0.71 Information Ratio 0.02 Alpha Ratio 3.75 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value Returns for SBI Healthcare Opportunities Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Sep 26 Duration Returns 1 Month 0.6% 3 Month 12.6% 6 Month 22.4% 1 Year 20.1% 3 Year 23.4% 5 Year 17.1% 10 Year 15 Year Since launch 15.7% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.5% 2024 42.2% 2023 38.2% 2022 -6% 2021 20.1% 2020 65.8% 2019 -0.5% 2018 -9.9% 2017 2.1% 2016 -14% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Data below for SBI Healthcare Opportunities Fund as on 31 Jul 26
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 4. UTI Healthcare Fund
UTI Healthcare Fund
Growth Launch Date 28 Jun 99 NAV (04 Sep 26) ₹342.841 ↓ -1.33 (-0.39 %) Net Assets (Cr) ₹1,371 on 31 Jul 26 Category Equity - Sectoral AMC UTI Asset Management Company Ltd Rating ☆ Risk High Expense Ratio 2.26 Sharpe Ratio 0.51 Information Ratio 0.05 Alpha Ratio 0.66 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value Returns for UTI Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Sep 26 Duration Returns 1 Month 1.8% 3 Month 12.1% 6 Month 23.2% 1 Year 17.2% 3 Year 23.9% 5 Year 15% 10 Year 15 Year Since launch 15.1% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.1% 2024 42.9% 2023 38.2% 2022 -12.3% 2021 19.1% 2020 67.4% 2019 1.2% 2018 -7.5% 2017 6.2% 2016 -9.7% Fund Manager information for UTI Healthcare Fund
Name Since Tenure Data below for UTI Healthcare Fund as on 31 Jul 26
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity
Benchmark: The Nifty Pharma Index
Pharma Mutual Funds generally track or take cues from the Nifty Pharma Index.
Key Highlights:
- Launched in 2005 by NSE.
- Represents major listed pharma companies.
- Includes top names like Sun Pharma, Dr. Reddy’s, Cipla, Divi’s Labs, Lupin, Aurobindo Pharma, etc.
- The index gives investors a snapshot of the overall sector’s performance.
To more about index can be read on official website Nifty Pharma Index Document
Who Should Invest in Pharma Mutual Funds?
Pharma funds are not for everyone. They are suitable if you are:
- An investor with high risk appetite who can handle sectoral Volatility.
- Looking to diversify your portfolio with exposure to a defensive but growing industry.
- A long-term investor (5+ years) seeking to benefit from structural growth trends in healthcare.
Not suitable for:
- Conservative investors.
- Those looking for short-term quick returns.
Pros & Cons of Investing in Pharma Funds
✅ Pros:
- Strong long-term growth drivers (domestic + exports).
- Defensive nature during downturns (people don’t stop consuming medicines).
- India’s global dominance in generics provides steady demand.
- Sector supported by government incentives.
❌ Cons:
- High volatility as it depends on global regulations (like USFDA warnings).
- Concentration risk – one sector only.
- Currency fluctuations affect export-heavy companies.
- Can underperform diversified funds during phases when pharma lags.
Unique Investor Angles to Consider
Here’s what most articles miss, but you should keep in mind:
Ageing Population = Permanent Demand
Globally, populations are ageing, particularly in developed countries. Indian companies are well-placed to serve this demand.
Shift Towards Wellness & Preventive Healthcare
Pharma is no longer just about medicines. Healthcare funds now capture hospitals, diagnostics, and preventive care businesses – expanding growth scope.
Regulatory Risk is Real
One USFDA ban can wipe out a stock’s value overnight. That’s why pharma funds spread risk across multiple companies.
Covid-19 Lesson
The pandemic proved how pharma can outperform when healthcare demand spikes – but it also showed the need to stay cautious about hype-driven rallies.
How to Invest in Pharma Sector Funds Online?
Open Free Investment Account for Lifetime at Fincash.com.
Complete your Registration and KYC Process
Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!
Public vs Private Healthcare: Why It Matters for Pharma Investors
India’s healthcare system is unique — while public hospitals account for only 30% of total hospital beds, the rest come from the private sector. This means the majority of patients depend on private care, which directly drives higher demand for medicines, diagnostics, and health insurance.
For pharma investors, this is critical. Unlike other industries, demand here is not cyclical — healthcare is a necessity. The more patients turn to private care, the more they rely on affordable medicines, making pharmaceutical companies long-term revenue generators.
The imbalance also highlights another important point: out-of-pocket expenditure in India is one of the highest in the world, around 48–50% of total healthcare spend. This forces households to prioritise low-cost drugs, generic medicines, and insurance-backed treatments — exactly the segments where Indian pharma companies have a competitive advantage.
Add to this the rise of medical tourism (expected to reach $13 billion+ by 2026), demand for speciality care in tier-2 cities, and a growing middle class that spends more on preventive healthcare. All of these trends ensure steady tailwinds for pharma companies and, by extension, pharma mutual funds.
This trend explains why pharma mutual funds are seen as a defensive bet — they combine healthcare demand certainty with the growth potential of India’s expanding private medical sector. In other words, the gap between public and private healthcare isn’t just a social challenge — it’s an investment signal, and one that smart investors can capture through pharma-focused fund.
Final Thoughts
Pharma Mutual Funds give investors a chance to tap into one of India’s strongest industries – with global leadership in generics, a growing domestic market, and government support. However, these are high-risk, high-reward funds. Don’t allocate more than 10–15% of your portfolio to sectoral funds, and always combine them with diversified mutual funds for stability.
If you believe in the long-term growth of healthcare and India’s role as the “Pharmacy of the World,” pharma funds can be a smart addition to your portfolio.
FAQs on Pharma Mutual Funds
Q1. Are pharma funds risky?
A: Yes, since they are concentrated sector funds. Suitable only for those who can take high risk.
Q2. How do pharma funds compare to diversified equity funds?
A: Diversified funds spread risk across sectors, pharma funds focus only on one. They can outperform in pharma bull runs but underperform otherwise.
Q3. What is the ideal investment horizon?
A: At least 5 years. Short-term Investing in sector funds is not recommended.
Q4. Are pharma funds good for SIPs?
A: Yes, SIPs help average out volatility in sectoral funds.
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
You Might Also Like
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2026 Shepard Technologies Private Limited. All Rights Reserved
Please send list of funds which has the option of changing the sector of funds so that overall performance of mutual funds are always very good. Thanks and Regards
Are largecap is best investment on longterm